Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval
Authors' conclusion
Lower baseline bone turnover and lower BMI may help identify postmenopausal Indian women in whom denosumab dosing can be safely deferred beyond six months.
Study context
- Population
- Postmenopausal Indian women with DXA-confirmed osteoporosis initiated on denosumab 60 mg SC, no prior anti-resorptive therapy
- Participants
- 56 women
- Exposure
- Delayed denosumab dosing vs standard dosing at 6 months
- Delayedn = 28
- Outcome
- Predictors (baseline bone turnover markers (BTMs), BMI) of delayed denosumab dosing beyond 6 months
Methodological detailsmultivariate logistic regression
- Multivariate logistic regression
Main finding
As reported in the abstract
Independent predictors of delayed denosumab administration (multivariate analysis)
- Lower baseline ß-CTX: OR 0.99 (95% CI 0.98-1.00), p = 0.027
- Lower body mass index (BMI): OR 0.60 (95% CI 0.40-0.89), p = 0.012
Observational data: associations, not effects.
Further findings
Baseline ß-CTX
P < 0.001
Baseline BMI
P = 0.005
- Dosing interval in Delayed
- 9.5 · median · months
Safety
New vertebral fractures during follow-up
- No new vertebral fractures observed in either group
Original publication
Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval. Osteoporos Int. Published 29 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →